Open AccessA Real-World Evaluation of Clinical Outcomes of Biologicals and Bronchial Thermoplasty for Severe Refractory Asthma (BIOTERM)
Author(s) -
Francesco Menzella,
Matteo Fontana,
Carla Galeone,
Maria D’Amato,
Giorgio Walter Caica,
Giulia Ghidoni,
Silvia Capobelli,
Chiara Scelfo,
Anna Simonazzi,
Chiara Catellani,
Patrizia Ruggiero,
Nicola Facciolongo
Publication year - 2021
Publication title -
journal of asthma and allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.162
H-Index - 30
ISSN - 1178-6965
DOI - 10.2147/jaa.s324099
Subject(s) - medicine , mepolizumab , omalizumab , bronchial thermoplasty , asthma , refractory (planetary science) , cohort , benralizumab , immunology , immunoglobulin e , antibody , physics , eosinophil , astrobiology , bronchoconstriction
The important progress made on asthma phenotyping encouraged the development of new therapeutic strategies, such as monoclonal antibodies (mAbs) and bronchial thermoplasty (BT). The aim of this study is to compare patients diagnosed with severe refractory asthma (SRA) who are currently being treated with omalizumab, mepolizumab, benralizumab or BT and to evaluate the efficacy of these treatments over a 12-month observation period.